Medication effects on midtrimester maternal serum screening.

OBJECTIVE: To determine whether medication classes are associated with alterations in concentrations of Quad screen analytes or the screen-positive rate. STUDY DESIGN: We conducted a retrospective cohort study of women with singleton gestations who received prenatal care and had a Quad screen performed in the University of Alabama at Birmingham system. Information on prescription medications was abstracted. Mean multiples of the medians for each analyte (alpha-fetoprotein, estriol, human chorionic gonadotropin, and inhibin A) and overall screening results were compared between those taking the class of medication and controls not taking any medications. RESULTS: There were 6206 women evaluated; 1337 took at least 1 prescription medicine and 4869 were controls. Mean analyte multiples of the medians were significantly different in women taking some medications compared with controls. Women taking certain medications had an increased screen-positive rate. CONCLUSION: Medications taken around the time of maternal serum screening are associated with alterations in individual analyte multiples of the medians, as well as the screen-positive rates.

Transforming growth factor-beta polymorphisms and cardiac allograft rejection.

BACKGROUND: Cytokine gene polymorphisms regulate cytokine expression. We analyzed transforming growth factor-beta (TGF-beta) allelic variation in codon 25 in susceptibility to acute rejection episodes in cardiac transplant recipients. METHODS: Between June 1997 and December 2001, 123 de novo heart transplants were performed at UAB with analysis based on 109 patients. Clinical and laboratory data were recorded at intervals up to 1 year post-transplant. Recipient genotypes for TGF-beta (codon 25) were determined using polymerase chain reaction (PCR) sequence-specific primers. Correlations between TGF-beta genotypes and acute rejection were made using Kaplan-Meier plots and parametric hazard models. RESULTS: Of the patients enrolled, 72% had at least one rejection and 46% had multiple rejections in the first year post-transplant. Among those > or =55 years of age at transplant, patients with the GG genotype had significantly fewer rejections as compared to those with the CC or GC genotype (1.25 vs 2.5, p < 0.01). There was no difference in risk of rejection between the genotype groups among patients <50 years of age at transplant (p = 0.43). Similar results were observed when we used time to cumulative Grade 2R or greater rejection as the outcome. CONCLUSION: The GG TGF-beta genotype may protect against acute rejection in older recipients during the first year after transplant.